BMS-933043 structure
|
Common Name | BMS-933043 | ||
---|---|---|---|---|
CAS Number | 1221973-93-8 | Molecular Weight | 325.368 | |
Density | 1.6±0.1 g/cm3 | Boiling Point | 539.3±60.0 °C at 760 mmHg | |
Molecular Formula | C16H19N7O | Melting Point | N/A | |
MSDS | N/A | Flash Point | 279.9±32.9 °C |
Use of BMS-933043BMS-933043 is a novel highly selective, potent α7 nAChR partial agonist with binding Ki of 3.3 and 8.1 nM for rat and human α7, respectively; displays high selectivity against other nAChR subtypes (>100-fold) and 5-HT3A receptor (>300-fold); demonstrates in vivo activity in a preclinical model of cognitive impairment, mouse novel object recognition. Schizophrenia Phase 1 Discontinued |
Name | N-[6-(1H-Imidazol-1-yl)-4-pyrimidinyl]-4'H-spiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxazol]-2'-amine |
---|---|
Synonym | More Synonyms |
Description | BMS-933043 is a novel highly selective, potent α7 nAChR partial agonist with binding Ki of 3.3 and 8.1 nM for rat and human α7, respectively; displays high selectivity against other nAChR subtypes (>100-fold) and 5-HT3A receptor (>300-fold); demonstrates in vivo activity in a preclinical model of cognitive impairment, mouse novel object recognition. Schizophrenia Phase 1 Discontinued |
---|---|
References | References 1. King D, et al. ACS Med Chem Lett. 2017 Feb 8;8(3):366-371. 2. Bristow LJ, et al. PLoS One. 2016 Jul 28;11(7):e0159996. 3. Weed MR, et al. PLoS One. 2017 Dec 19;12(12):e0187609. View Related Products by Target nAChR Schizophrenia |
Density | 1.6±0.1 g/cm3 |
---|---|
Boiling Point | 539.3±60.0 °C at 760 mmHg |
Molecular Formula | C16H19N7O |
Molecular Weight | 325.368 |
Flash Point | 279.9±32.9 °C |
Exact Mass | 325.165100 |
LogP | 0.27 |
Vapour Pressure | 0.0±1.4 mmHg at 25°C |
Index of Refraction | 1.815 |
Spiro[1-azabicyclo[2.2.2]octane-3,5'(4'H)-oxazol]-2'-amine, N-[6-(1H-imidazol-1-yl)-4-pyrimidinyl]- |
N-[6-(1H-Imidazol-1-yl)-4-pyrimidinyl]-4'H-spiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxazol]-2'-amine |